

Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1-45. (canceled)

46. (currently amended) A method for enhancing an immune response to an antigen in an individual to which said antigen is administered comprising administering to said individual an amount, effective to enhance said immune response, of a composition comprising a *Quillaja saponaria* saponin adjuvant and an excipient, said excipient being selected from the group consisting of a β -cyclodextrin, and a deacylsaponin, ~~a Polysorbate, and Triton X-100.~~

47. (previously presented) The method of claim 46, wherein the saponin adjuvant is a heterogeneous saponin adjuvant.

48. (previously presented) The method of claim 47, wherein the heterogenous saponin adjuvant is Quil-A.

49. (previously presented) The method of claim 46, wherein the saponin adjuvant comprises two or more substantially pure saponins selected from the group consisting of QS-7, QS-17, QS-18, and QS-21.

50. (previously presented) The method of claim 46, wherein the saponin adjuvant is a substantially pure saponin adjuvant.

51. (previously presented) The method of claim 50, wherein the substantially pure saponin adjuvant is selected from the group consisting of QS-7, QS-17, QS-18 and QS-21.

52. (previously presented) The method of claim 50, wherein the substantially pure saponin adjuvant is QS-21.

53. (canceled)

54. (previously presented) The method of claim 46, wherein the antigen is a polysaccharide, a lipid, or a nucleic acid.

55-57. (canceled)

58. (currently amended) The method according to ~~claim 46~~ any of claims 46-53, wherein the excipient is a β -cyclodextrin.

59. (currently amended) The method according to ~~claim 58~~ any of claims 46-53, wherein the ~~β -cyclodextrin~~ excipient is hydroxypropyl- β -cyclodextrin.

60. (canceled)

61. (previously presented) The method of claim 46, wherein the excipient is a deacylsaponin ("DS").

62. (previously presented) The method of claim 61, wherein the excipient is DS-1.

63. (previously presented) The method of claim 46 or 52, wherein said antigen and said composition are administered to said individual concurrently.

64. (previously presented) The method of claim 46, wherein said individual is a mammal.

65. (currently amended) The method of any one of claims 46-54, ~~56 and 58~~, wherein said individual is a human.

66. (previously presented) The method of claim 63, wherein said individual is a human.

67. (currently amended) The method of claim 46, 47, 51 or 52, ~~56, or 58~~, wherein the antigen is a peptide or a protein.

68. (previously presented) The method of claim 67, wherein said individual is a human.

69. (new) The method of claim 58, wherein said individual is a human.

70. (new) The method of claim 58, wherein the antigen is a peptide or protein.